Filing Details
- Accession Number:
- 0001739614-21-000039
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-02-18 17:06:49
- Reporting Period:
- 2021-02-16
- Accepted Time:
- 2021-02-18 17:06:49
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1739614 | Inhibrx Inc. | INBX | Biological Products, (No Disgnostic Substances) (2836) | 824257312 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1766477 | W. Klaus Wagner | C/O Inhibrx, Inc. 11025 North Torrey Pines Road, Suite 200 La Jolla CA 92037 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2021-02-16 | 156,474 | $24.32 | 234,709 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-02-17 | 19,559 | $25.29 | 215,150 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan on September 14, 2020.
- The shares were sold in multiple transactions at prices ranging from $22.14 to $32.50, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- The shares were sold in multiple transactions at prices ranging from $25.00 to $25.50, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Billionaire Hedge Funds
